跳至主要内容
临床试验/NCT03524339
NCT03524339已完成2 期

Perioperative Administration of Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery

University Hospitals Cleveland Medical Center2 个研究点 分布在 1 个国家目标入组 132 人开始时间: 2018年8月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
132
试验地点
2
主要终点
Postoperative Urinary Retention

研究概览

简要总结

This is a placebo controlled randomized controlled trial of perioperative use of tamsulosin to prevent postoperative urinary retention in female pelvic reconstructive surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients must be 18 years or older as well as willing and able to provide informed consent
  • Patients must be undergoing a scheduled surgery for pelvic organ prolapse or urinary incontinence
  • Standard postoperative plan must include admission to the hospital with foley catheterization overnight the night after surgery, and planned removal of foley catheter and active voiding trial on postoperative day 1.

排除标准

  • Patient unable or unwilling to provide informed consent
  • Severe allergy to sulfa drugs
  • Known allergy to tamsulosin or another alpha antagonist medication
  • History of urinary retention
  • Planned bladder catheterization greater than 24 hours after surgery
  • Current use of alpha antagonist medication for hypertension
  • End stage renal or liver disease

研究组 & 干预措施

Placebo

Placebo Comparator

干预措施: Placebo oral capsule (Drug)

Tamsulosin

Experimental

干预措施: Tamsulosin (Drug)

结局指标

主要结局

Postoperative Urinary Retention

时间窗: Within 72 hours of surgery

Failed voiding trial upon removal of catheter

次要结局

  • Sent Home With Catheterization(within 6 weeks of surgery)
  • Postoperative Urinary Tract Infection(Within 6 weeks after surgery)
  • International Prostate Symptom Score(Within 1 week of surgery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Graham Chapman

Principal Investigator

University Hospitals Cleveland Medical Center

研究点 (2)

Loading locations...

相似试验